April 8 (Reuters) - GENFIT SA GNFT.PA :
* ANNOUNCED ON THURSDAY ITS 2021 ANNUAL FINANCIAL RESULTS
AND
BUSINESS UPDATE ACTIVITIES OF THE COMPANY
* FY REVENUE AMD OTHER OPERATING INCOME EUR 85.6 MLN VS EUR
7.8
MLN YEAR AGO
* FY NET RESULT UP AT EUR 67.3 MLN VS LOSS EUR 101.2 MLN
YEAR AGO
* CASH AND CASH EQUIVALENTS TOTALED EUR 258.8 MLN AS OF
DECEMBER
31, 2021
* OUTLOOK 2022: ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS
(PBC):
CONFIRMATION OF TARGET TO ANNOUNCE FIRST RESULTS IN Q2 2023
* OUTLOOK 2022: NTZ IN ACLF: PHASE 1 RESULTS EXPECTED IN Q3
2022
* OUTLOOK 2022: GNS561 IN CCA: START OF PHASE 1B/2 CLINICAL
TRIAL
PLANNED FOR Q4 2022
* OUTLOOK 2022: PBC: CONFIRM OBJECTIVE OF ANNOUNCING FIRST
RESULTS
IN Q2 2023, IN LINE WITH PREVIOUS ESTIMATES
Source text for Eikon: urn:newsml:reuters.com:*:nGNE9xlVVX
Further company coverage: GNFT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))